N-terminal pro-brain natriuretic peptide and electrocardiographic variables associated with increased risk of complete atrioventricular block and mortality in patients with acute inferior myocardial infarction by Geyik, Bilal et al.
479www.cardiologyjournal.org
ORIGINAL ARTICLE
Cardiology Journal
2012, Vol. 19, No. 5, pp. 479–486
10.5603/CJ.2012.0088
Copyright © 2012 Via Medica
ISSN 1897–5593
Address for correspondence: Damirbek Osmonov, MD, Mimar Sinan cad. 89/3 Ornek Mah, Atasehir, Istanbul, Turkey,
tel: 00-90-216-4189610, fax: 00-90-216-3379719, e-mail: damirbeko@yahoo.com
Received: 22.05.2012 Accepted: 19.06.2012
N-terminal pro-brain natriuretic peptide and
electrocardiographic variables associated with
increased risk of complete atrioventricular block
and mortality in patients with
acute inferior myocardial infarction
Bilal Geyik1, Ozcan Ozdemir2, Damirbek Osmonov3, Mustafa Ozcan Soylu3
1Department of Cardiology, Trakya University School of Medicine, Edirne, Turkey
2Department of Cardiology, Akay Hospital, Ankara, Turkey
3Department of Cardiology, German Hospital, Istanbul, Turkey
Abstract
Background: Although brain natriuretic peptide (BNP) levels are shown to be an important
prognostic factor in patients with acute myocardial infarction (MI), the relationship between
arrhythmias and BNP levels is not known. This study assessed whether baseline clinical
factors, N-terminal-proBNP (NT-proBNP) levels and electrocardiographic patterns of acute
inferior MI are associated with greater risk of developing complete atrioventricular block
(CAVB) and mortality.
Methods and Results: Seventy-nine consecutive patients (52 male, 27 female with an
avarage age of 64.2 ± 10.9 years) with CAVB and 119 control patients (93 male, 16 female
with an average age of 57.7 ± 11.4 years) without CAVB were enrolled. Regression analysis
revealed that NT-proBNP levels > 104 pg/mL increased the development of CAVB by
16.7 folds, > 1 mm ST elevation in RV4 by 2.7 folds, ratio of elevation in lead III:II > 1.5 by
10.1 folds but the thrombolytic therapy decreased the development of CAVB by 2.8 folds.
NT-proBNP > 92 pg/mL increased the mortality by 8.9 folds, a ratio of ST-segment elevation
in lead III:II > 1 by 3.1 folds, ST segment elevation > 1 mm in RV4 by 3.5 folds, ejection
fraction < 35% by 24.2 folds, age > 65 years by 8.3 folds and CAVB by 6.8 folds, on contrary
thrombolytic treatment decreased the mortality by 3.3 folds.
Conclusions: Simple electrocardiographic measurements and NT-proBNP levels at
admission can be used as a screening test for development of complications such as CAVB,
right ventricular involvement and mortality during acute inferior wall MI. (Cardiol J
2012; 19, 5: 479–486)
Key words: complete atrioventricular block, ST-segment elevation inferior
myocardial infarction, brain natriuretic peptide
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Introduction
Inferior wall acute myocardial infarction (MI)
is often complicated by atrioventricular (AV) block
with an incidence varying from 8 to 20% [1–3] du-
ring the hospital course. Several investigators re-
port that larger infarctions are associated with AV
block, a high incidence of in-hospital complications
and an increased short term mortality rate occur
among the patients with complete AV block (CAVB)
[1–4]. Therefore, it is important to define the pa-
tients with a high-risk for the development of CAVB
since the clinician managing such patients must
decide whether to place a prophylactic pacemaker.
Some electrocardiographic (ECG) markers are
shown to be useful in identifying the location of the
totally occluded coronary artery [5] and in predict-
ing in-hospital mortality in acute inferior wall MI
[6]. Although higher brain natriuretic peptide (BNP)
levels are shown to be an important prognostic fac-
tor for short- and long-term in patients with acute
MI [7–10], the relationship between arrhythmias
and BNP levels is not known.
This study assessed whether baseline clinical
factors, N-terminal-proBNP (NT-proBNP) levels
and ECG patterns of acute inferior MI are associ-
ated with greater risk of developing CAVB and
mortality.
Methods
Study sample
Consecutive 787 patients admitted to our clinics
with their first ST elevation inferior MI were inclu-
ded in our study. A written consent was obtained
from all patients and our local ethics committee
approved the study [11]. Blood samples were ob-
tained on admission and every 3 h during the first
24 h, every 6 h for the next 2 days and daily until
discharge. Peak CK-MB level was estimated for
each patient. All the patients were monitored for at
least 3 days but the patients with rhythm disorders
until discharge. CAVB was defined by standard
criteria: complete dissociation of atrial and ventri-
cular rates with the atrial rate greater than ventri-
cular rate. Ventricular arrhythmias were classifed
as Lown criterias [12] and an arrhythmia with
a grade > 3 and ventricular fibrillation were con-
sidered significant. The patients with a history of
previous MI, percutaneous or surgical revascula-
rization, significant valvular disease and the patients
with first-degree, Mobitz type I and II AV block, left
anterior and posterior hemiblock, bundle branch
block and atrial fibrillation were excluded.
Electrocardiographic evaluation
All the patients enrolled in this study had an
ECG obtained before the development of CAVB and
measurements were performed on this ECG. ECGs
were also taken at the time of the patients’ admis-
sion to the hospital and at least at intervals of 6 h
for the first 2 days at a paper speed of 25 mm/s and
an amplification of 10 mm/mV. The ECGs were re-
viewed blindly by two cardiologists without know-
ledge of the patient’s clinical course and the study
design. ST segment elevation was measured 0.08 s
after the J point in leads II, III, aVF and aVR, to an
accuracy of 0.5 mm. At least 2 consecutive QRS
complexes were measured with the PQ segment
used as the isoelectric line and the mean value re-
corded for each lead. Each patient was analyzed for
the presence of ST elevation > 1 mm in lead V4R,
the ratio of ST elevation in leads III/II, the presence
of ST depression in lead aVL > 1 mm.
Coronary angiography
Coronary angiography was performed in 169 pa-
tients at the 3–5th day after admission. Coronary
artery lesions with ≥ 50% reduction in diameter
were considered significant. Angiographically visi-
ble collaterals were graded as follows: 0 = no col-
laterals, 1 = incomplete slow opacification of the
distal vessel, 2 = slow but complete opacification
of the distal vessel and 3 = distal vessel opacified
as the normal vessel [13]. Good collateral filling was
classified as grade 2 or 3 and poor collateral filling
as grade 0 or 1. The proximal right coronary artery
(RCA) lesion was defined as a lesion before the
acute marginal branch. Angiograms were analyzed
by 2 experienced angiographers without the know-
ledge of clinical and ECG findings. Culprit lesion or
infarct-related artery (IRA) was defined when the
lesion was totally occluded or showed severe
stenoses (> 90–95% obstruction).
Echocardiography
Two-dimesional and M-mode transthoracic
echocardiography were performed at the 3rd day
after admission and left ventricular systolic func-
tions were evaluated. Left ventricular ejection frac-
tion (LVEF) was estimated from apical four-cham-
ber view using Simpson method [14].
Measurement of NT-proBNP plasma levels
Peripheral venous blood samples were collect-
ed into EDTA-containing tubes for each subject at
rest at admission. The samples were centrifuged
within 20 min at +4oC. The plasma was stored at
–80oC until analysis. Serum NT-proBNP was mea-
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sured by a double antibody sandwich technique us-
ing electrochemiluminescence immunoassay kit
(Roche Diagnostics). The results were reported as
picogram per milliliter [pg/mL]. The clinicians
involved in the study were blinded to the NT-
-proBNP values obtained.
Statistical analysis
Continous variables are presented as mean ±
± standard deviation and discrete variables are ex-
pressed as frequencies and percentages. For con-
tinous variables, differences between patients with
and without CAVB were tested using Student’s
t-test, and for categorical variables c2 (or Fischer’s
exact test) was used. A receiver operating characte-
ristic curve was used to evaluate the various sensiti-
vities and specificities at different cutpoints of some
ECG and clinical variables besides NT-proBNP.
Multivariate logistic regression techniques were
used to developed a model to predict CAVB and in-
hospital mortality. A p value < 0.05 was considered
statistically significant.
Results
Seventy-nine consecutive patients (52 male,
27 female with an average age of 64.2 ± 10.9 years)
with CAVB and 119 control patients (93 male,
16 female with an average age of 57.7 ± 11.4 years)
without CAVB were enrolled in this study. Sixty-
-six (83.5%) of the patients with CAVB and 100
(84%) of the control group underwent coronary
angiography. The mean blood pressure on admis-
sion, hyperlipidemia, thrombolytic treatment and
EF were lower, hypertension (HT), syncope, pace-
maker implantation, peak CK-MB levels, NT-pro-
BNP levels, 3-vessel disease, left anterior descend-
ing artery (LAD) stenosis > 50%, RCA stenosis,
proximal RCA lesion, hospitalization time, ventri-
cular arrhythmias, in-hospital mortality were high-
er in the patients with CAVB compared to those
without AV block (Table 1). ST segment elevation
in leads III and aVF, the ratio of ST elevation in III:II
and aVF:II, ST segment elevation > 1 mm in RV4
and ST depression > 1 mm in aVL on admission
were significantly higher in the patients with CAVB
(Table 2). Temporary endocardial ventricular pace-
makers were installed in 71 (90%) patients, but
permanent pacemaker implantation was performed
only in 3 (4%) patients.
Of the 79 patients, 68 (86%) developed CAVB
during the first 24 h after the onset of symptoms
and they constituted the early AV block group. Ele-
ven (13.9%) patients developed CAVB after 24 h
and they compromised the late AV block group. There
were no significant difference in age, sex, cardiac
risk factors, presence of previous angina history,
ST-segment elevation in leads II, III, aVF, RV4, ST
depression in aVL, thrombolytic treatment, peak
CK-MB levels, EF, the need for pacemaker implan-
tation, 3-vessel disease, RCA stenosis, IRA, collat-
eral development, in-hospital mortality. The ratio
of ST elevation in lead III:II was greater (1.8 ± 0.5
vs. 1.5 ± 0.4, p = 0.002), NT-proBNP levels on
admission were higher (133.1 ± 62.9 vs. 128.3 ±
± 32.5, p = 0.001) and proximal RCA lesion was
higher (92% vs. 75%, p = 0.002) in the early AV
block compared to the late AV block group. The
patients with late CAVB had also higher NT-pro-
BNP levels than those without CAVB (128.3 ± 32.5
vs. 86.4 ± 30.1, p = 0.008).
Correlation analysis showed that NT-proBNP
levels were correlated with ST-elevations in leads
III and aVF. Moreover, NT-proBNP levels were
correlated with peak CK-MB levels (r = 0.4, p =
= 0.001) and LVEF (r = –0.4, p = 0.001). Other
correlations were shown in Table 3.
A ratio of ST-segment elevation in lead III:II
> 1.5 separated the patients with CAVB from con-
trol subjects with a sensitivity of 70%, specificity
of 68% and a positive predictive accuracy of 70%.
An NT-proBNP level > 104 separated the patients
with CAVB from control subjects with a sensitivity
of 72%, specificity of 79% and a positive predictive
accuracy of 70%. Regression analysis revealed that
NT-proBNP levels > 104 increased the develop-
ment of CAVB by 16.7 folds, proximal RCA lesion
by 3.9 folds, LAD stenosis > 50% by 1.2 folds,
> 1 mm ST elevation in RV4 by 2.7 folds, ratio of
elevation in lead III:II > 1.5 by 10.1 folds but the
thrombolytic therapy decreased the development
of CAVB by 2.8 folds (Table 4).
The patients who died during the hospitaliza-
tion were older (71.6 ± 8.3 vs. 58.5 ± 11.1, p =
= 0.001), had higher ST elevation in lead III (3.9 ±
± 1.9 vs. 2.9 ± 1.6, p = 0.009), higher CK-MB levels
(233.1 ± 58.1 vs. 138.1 ± 36.9, p = 0.001), lower
EF (39.7 ± 4.6 vs. 47.2 ± 5.8, p = 0.001) than those
who survived. Those patients had also higher CAVB
ratio (74% vs. 34%, p = 0.001), right ventricle in-
volvement (81% vs. 28%, p = 0.001), 3-vessel dis-
ease (77% vs. 34%, p = 0.006), higher ventricular
arrhythmia rate (56% vs. 7%, p = 0.001). ST-seg-
ment elevation in lead III > 3.25 mm in the admis-
sion ECG seperated the patients who died during
the hospitalization from those who survived by
a sensitivity of 63%, specificity of 70% and a positive
predictive accuracy of 66%. NT-proBNP > 92 pg/mL
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increased the mortality 8.9 folds (sensitivity 88%,
specificity 62%). A ratio of ST-segment elevation
in leads III:II > 1 by 3.1 folds, ST segment eleva-
tion > 1 mm in RV4 by 3.5 folds, peak CK-MB
> 166 IU/mL by 3.2 folds, EF < 35% by 24.2 folds,
RCA stenosis > 95% by 3.6 folds, LAD stenosis
Table 2. Comparison of electrocardiographic findings of the patients with and without complete atrio-
ventricular block (CAVB) on admission.
Electrocardiographic variables Patients with CAVB Patients without CAVB P
(n = 79)  (n = 119)
Atrial rate on admission [bpm] 70 ± 12 71 ± 15 0.6
Ventricular rate on admission [bpm] 45 ± 12 71 ± 15 0.001
ST elevation in lead II 2.5 ± 1.2 2.2 ± 3.2 0.3
ST elevation in lead III 4.0 ± 1.7 2.4 ± 1.3 0.001
ST elevation in aVF 3.2 ± 1.5 1.9 ± 1.1 0.001
ST elevation D3/D2 1.7 ± 0.4 1.4 ± 0.5 0.001
ST elevation aVF/D2 1.3 ± 0.3 1.1 ± 0.4 0.001
> 1 mm ST depression in aVL (%) 63 (80%) 78 (65%) 0.03
> 1 mm ST elevation in RV4 (%) 48 (61%) 21 (18%) 0.001
Table 1. Comparison of patients with and without complete atrioventricular block.
Variables Patients with CAVB Patients without CAVB P
(n = 79)  (n=119)
Age [years] 64.2 ± 10.9 57.7 ± 11.4 0.001
Male patients 52 (65%) 93 (78%) 0.06
Mean blood pressure on admission [mm Hg] 65 ± 15 89 ± 13 0.001
Diabetes mellitus 27 (34%) 35 (29%) 0.5
Hypertension 43 (54%) 37 (31%) 0.001
Hyperlipidemia 19 (24%) 50 (42%) 0.01
Smoking 37 (47%) 58 (49%) 0.8
Previous angina 42 (53%) 56 (47%) 0.4
Syncope 40 (51%) 2 (2%) 0.001
Thrombolytic treatment 54 (68%) 97 (82%) 0.02
Temporary pacemaker 71 (90%) 0 0.001
Permanent pacemake 3 (4%) 0 0.001
Peak CK-MB levels [IU/mL] 183.9 ± 64.6 142.6 ± 39.3 0.01
Pro-BNP [pg/mL] 131.7 ± 55.7 86.4 ± 30.1 0.001
Ejection fraction (%) 44.9 ± 5.8 47.0 ± 6.4 0.02
IRA:
CX 10 (15) 27 (26) 0.5
RCA 56 (85) 76 (74) 0.09
RCA stenosis (%) 86.6 ± 20.6 70.6 ± 35.1 0.001
LAD stenosis > 50% 31 (47%) 32 (31%) 0.02
3-vessel disease 31(47) 32(31) 0.02
Proximal RCA lesion 50 (89%) 48 (65%) 0.01
Well-developed collaterals 14 (21%) 33 (33%) 0.1
Ventricular arrhythmia 23 (30%) 10 (9) 0.001
Hospitalization time [day] 8.2 ± 5.1 6.1 ± 2.2 0.001
In-hospital mortality 21 (26%) 6 (5%) 0.001
CAVB — complete atrioventricular block; CK-MB — myocardial band fraction of creatine kinase; BNP — brain natruretic peptide; IRA — infarct
related artery; RCA — right coronary artery; CX — circumflex artery; LAD — left anterior descending artery
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> 50% by 3.8 folds, age > 65 years by 8.3 folds,
ventricular rate < 36 bpm on admission by 2.8 folds,
CAVB by 6.8 folds on contrary thrombolytic treat-
ment decreased the mortality by 3.3 folds (Table 5).
Discussion
The main findings of this study: 1) A ratio of
ST segment elevation in leads III/II; 2) > 1 mm ST
elevation in RV4; 3) ST elevation in lead III; 4) Pro-
ximal RCA lesion; 5) LAD stenosis; 6) Older age;
7) NT-proBNP are significant predictors for CAVB and
mortality in the patients with acute inferior wall MI.
CAVB is a frequent complication of inferior MI
that is associated with a high incidence of in-hos-
pital morbidity and mortality [1–4, 15, 16]. Con-
duction defects complicated acute MI have a gra-
ded impact on short-term prognosis [3, 17–21].
Although Chen et al. [22] showed that thrombolytic
therapy can reduce the incidence of severe AV
block, shorten its duration and decrease mortali-
ty, Ben Ameur et al. [23] noted that thrombolysis
does not affect the incidence of AV block but im-
proves the outcomes of these patients. Despite the
initial successful reperfusion, the patients with
acute inferior MI and CAVB have a higher rate of
in-hospital complications and mortality [2]. In our
study, CAVB was shown to increase in-hospital
mortality by 6.8 folds independent to the thrombo-
lytic therapy.
Table 3. Correlations between electrocardiographic parameters and laboratory.
Variables SST in II SST in III SST in aVF SST III/II Basal HR
NT-proBNP r = 0.03 p = 0.3 p = 0.3 p = 0.1 r  = 0.2
p = 0.7 p = 0.001 p = 0.001 p = 0.09 p = 0.3
LVEF r = –0.2 p = –0.5 p = –0.5 p = –0.02 r = 0.01
p = 0.01 p = 0.001 p = 0.001 p = 0.8 p = 0.9
CK-MB r = 0.3 p = 0.5 p = 0.5 p = 0.03 r = 0.2
p = 0.001 p = 0.002 p = 0.002 p = 0.7 p = 0.3
Stenosis degree in RCA r = 0.03 p = 0.02 p = 0.01 p = 0.1 r = 0.2
p = 0.7 p = 0.08 p = 0.9 p = 0.2 p = 0.3
NT-proBNP — N-terminal-pro-brain natriuretic peptide; LVEF — left ventricular ejection fraction; CK-MB — myocardial band fraction of creatine kinase;
RCA — right coronary artery; HR — heart rate
Table 4. The factors affecting the development
of complete atrioventricular block in patients
with acute inferior wall myocardial infarction.
Variables b SE RR P
Age > 65 0.02 0.04 1.1 0.6
Hypertension 0.8 0.9 1.5 0.5
Hyperlipidemia –0.5 0.8 –2.7 0.6
Thrombolytic treatment –0.8 0.9 –2.8 0.02
> 1 mm ST depression 1.2 1.2 2.1 0.3
in aVL
> 1 mm ST elevation 1.1 0.8 2.7 0.02
in RV4
ST elevation in 2.1 0.6 2.3 0.01
lead III > 2.75 mm
ST elevation D3/D2 > 1.5 4.6 1.7 10.1 0.007
Proximal RCA lesion 1.4 0.6 3.9 0.02
LAD stenosis > 50% 1.0 0.6 1.2 0.03
Collaterals to IRA –1.1 0.9 3.3 0.3
NT-proBNP > 104 2.7 1.1 16.7 0.006
LAD — left anterior descending artery; IRA — infarct related artery;
NT-proBNP — N-terminal-pro-brain natriuretic peptide
Table 5. Factors affecting mortality in the patients
with acute inferior wall myocardial infarction.
Variables b SE RR P
Age > 65 2.1 0.5 8.3 0.001
CAVB 3.0 0.5 6.8 0.001
ST elevation 1.3 0.4 3.8 0.002
in lead III > 3.25
ST elevation 1.1 0.6 3.1 0.001
D3/D2 > 1
> 1 mm ST elevation 1.3 0.8 3.5 0.001
in RV4
Peak CK-MB > 166 4.8 1.0 3.2 0.001
Ejection fraction < 35% 3.1 0.9 24.2 0.001
RCA stenosis > 95% 1.2 0.5 3.6 0.003
LAD stenosis > 50% 1.7 0.7 3.8 0.002
Thrombolytic treatment –0.8 0.6 –3.3 0.001
Ventricular rate on 1.0 0.6 2.8 0.04
admission < 36 bpm
NT-proBNP > 92 pg/mL 2.2 0.8 8.9 0.005
CAVB — complete atrioventricular block; CK-MB — myocardial band
fraction of creatine kinase; RCA — right coronary artery; LAD — left
anterior descending artery; NT-proBNP — N-terminal-pro-brain
natriuretic peptide
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A number of studies have assessed the in-hos-
pital significance of AV block in acute inferior MI
[1–4, 20–24]. In-hospital mortality rates are vary-
ing from 8 to 45% [1–4, 20–24]. The hospital mor-
tality in the patients who developed CAVB was 26%
in our study and much higher compared to those
without CAVB (5%). The increased risk of early
mortality in these patients may be related to several
factors: larger infarct, ischemia at a distance,
increased electrical instability and more severe
right or left ventricular dysfunction [25]. Previous
studies have shown that the patients with CAVB
and inferior MI have a large infarct size and in-
creased in-hospital mortality despite thrombolytic
treatment [24–26]. In our study, the peak CK-MB
levels were higher and LVEF was lower in the pa-
tients with CAVB compared to those without
CAVB. In addition, an EF < 35% was found to in-
crease the mortality by 24.2 folds and a peak CK-
-MB levels > 166 IU/mL by 3.2 folds. However,
Kimura et al. [15] found that peak CK activity and
QRS score at discharge are similar in the patients
with and without CAVB. An NT-proBNP level
> 92 pg/mL increased the mortality by 8.9 folds in our
study. This may be explained by two proposals.
First, high level of BNP is a powerful marker of LV
systolic dysfunction and poor prognosis after MI
[7–10]. In patients with acute MI, increases in plasma
BNP concentration during the early phase reflect
MI size, and thereby may predict later LV function
[7–10, 27]. Accordantly, NT-proBNP levels were
found to be correlated with LVEF and peak CK-MB
levels in our study. Secondly, higher BNP level may
reflect right ventricular involvement in patients
with inferior MI [28]. Similarly, we found that the
patients (n = 74) with ST elevation > 1 mm in RV4
had higher NT-proBNP levels (138.5 ± 45.9 pg/mL
vs. 79.3 ± 22.9, p = 0.001) compared to those with-
out. NT-proBNP level > 95 pg/mL separated the
patients with right ventricular involvement by
a sensitivity of 98% and a specificity of 77%.
NT-proBNP level > 95 pg/mL increased the risk of
right ventricular involvement by 12.9 folds (b = 4.9,
p = 0.001). Right ventricular involvement in the
patients with acute inferior MI is reported to have
a higher rate of major complications and in-hospital
mortality [29]. Similarly, we found that ST segment
elevation > 1 mm in RV4 increased the mortality
in the patients with acute inferior MI by 3.5 folds.
Moreover, right ventricular involvement identifies
high risk developing AV nodal conduction disturbanc-
es in the patients with inferior MI [30]. In our study,
> 1 mm ST elevation in RV4 increased the develop-
ment of CAVB by 3.7 folds. In another study,
although early CAVB is shown to be related to a more
extensive area at risk, the clinical features are found
to depend on the atrial rate during CAVB [31, 32]. We
found that a ventricular rate < 36 bpm at admission
increase the mortality by 2.8 folds in acute inferior MI.
Some electrocardiographic risk factors such as
first-degree, Mobitz type I and II AV block, bundle
branch block, left anterior and posterior hemiblock
were defined to predict the occurrence of CAVB
[16]. Previous 2 reports noted that patients with
J-point/R-wave ratio ≥ 0.5 in ≥ 2 inferior leads
(II, III and aVF), female patients and the patients
with higher Killip class on admission (≥ 2) have an
increased risk for development of high-degree AV
block in inferior wall acute MI [33, 34]. In our study,
we found that ST elevation in lead III greater than
in II and a ratio of ST segment elevation in leads
III/II > 1.5, > 1 mm ST elevation in RV4, ST ele-
vation in lead III > 2.75 mm, ST elevation in aVF
> 2.75 mm, ST elevation aVF/DII > 1.0 are signi-
ficant predictors for CAVB in the patients with acute
inferior wall MI. As to clinical variables, the patients
older than 65 years have higher risk of CAVB de-
velopment. Similarly, Meine et al. [20] reported that
significant independent predictors of AV block are
inferior MI, older age, worse Killip class at presen-
tation, female sex, current smoking, hypertension,
and diabetes. The prevalence of stenosis in LAD
was much higher in the patients with CAVB. We
found that LAD stenosis is one of the predictors for
CAVB development in the patients with inferior
wall acute MI. Similar to our results, Bassan et al.
[35] showed that patients with AV block during
acute inferior wall MI has a significantly higher
prevalence of LAD obstruction. These findings also
support the observations that the proximal AV con-
duction system usually has a dual arterial blood
supply from both the right and left anterior descend-
ing coronary arteries. Proximal RCA lesion is found
to be associated with a higher risk of high-degree
AV block development [36]. In most of the patients
with acute inferior MI, there is a total occlusion of
the proximal RCA [26]. Greater ST elevation in lead
III than II is a sensitive and specific marker of RCA
occlusion [37]. Moreover, Zimetbaum et al. [5] de-
monstrated that the presence of ST-segment ele-
vation in lead III>II is a powerful predictor of oc-
clusion of the proximal or mid portion of the RCA
in the patients with acute inferior MI. Accordantly
in our study, proximal RCA lesion and a ratio of
ST segment elevation in leads III/II > 1.5 were in-
dependent predictors of CAVB and increased the
development of CAVB by 2.9 and 3.7 folds, respec-
tively.
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Although higher BNP levels are shown to be
an important prognostic factor for short- and long-
-term in patients with acute MI [7–10], the relation-
ship between arrhythmias and NT-proBNP levels
is not known. Higher BNP levels are useful for iden-
tification of hypertrophic cardiomyopathy patients
[38], heart failure patients [39] who have a risk of
atrial fibrillation. The plasma levels of NT-proBNP
in patients with bradyarrhythmia increased in pro-
portion to aggravation of AV asynchrony [40]. Koch
et al. [41] found that high degree AV block can in-
duce elevated plasma BNP levels and the loss of AV
synchrony induce a further increase of BNP. There-
fore, the increase in NT-proBNP in patients with
CAVB during acute inferior MI is not surprising.
But the patients with late CAVB had also higher
NT-proBNP levels at admission than control group
suggesting that NT-proBNP levels may be useful
for identification of the patients with acute inferior
MI who have a high risk for high degree AV block.
Limitations of the study
Patients with their first ST elevation inferior
MI who are managed with medical therapy/throm-
bolytics in the acute setting were evaluated. Obser-
vations cannot be generalized to patients with pre-
vious MI or those whom performed a primary per-
cutaneous coronary intervention.
Conclusions
As a result, these simple electrocardiographic
measurements and NT-proBNP levels at admission
can be used as a screening test for development of
complications such as CAVB, right ventricular in-
volvement and mortality during acute inferior wall
myocardial infarction. And the clinician managing
such patients should either observe more cautiously
for a potentially unstable condition or should apply
much more invasive procedures such as percuta-
neous coronary interventions or a prophylactic
pacemaker implantation.
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